Promising novel therapies for the treatment of endometrial cancer.
Promising novel therapies for the treatment of endometrial cancer.
复制标题
治疗子宫内膜癌的有前景的新疗法。
DOI：
10.1016/j.ygyno.2009.10.041
复制
发表时间：
2010-02
影响因子：
4.7
通讯作者：
Bae-Jump VL
中科院分区：
文献类型：
--
作者：
Gehrig PA;Bae-Jump VL
讨论正在开发的用于治疗晚期和复发性子宫内膜癌的新药物，并回顾可能在治疗这种疾病中感兴趣的其他分子靶点。虽然大多数患有子宫内膜癌的妇女享有相对良好的预后，但那些患有疾病复发的妇女的选择有限，需要确定新的药物。综述了新型治疗药物及其分子靶点的临床试验。此外，对目前关于子宫内膜癌其他潜在分子靶点的文献进行了综述。几个II期试验的新药物，无论是单独和与传统的细胞毒性化疗组合，已经完成或接近完成。似乎靶向药物与细胞毒性化疗或多靶向药物方法联合使用可能具有最大疗效。化疗为子宫内膜癌患者提供了有意义的缓解率的机会，但这些缓解往往是短暂的，并且在复发性疾病中治愈是罕见的。最近分子靶点的增加导致了许多新疗法的可用性。确定如何使用这些药物，单独或与“标准”疗法相结合，需要定义和转化研究，以开发这些新药物的合理组合，然后才能进入临床试验。
To discuss the novel agents which are being developed for the treatment of advanced and recurrent endometrial carcinoma and to review other molecular targets that may be interesting in the treatment of this disease. While the majority of women with endometrial cancer enjoy a relatively good prognosis, the options for those women who suffer from a disease recurrence are limited and there is a need to identify novel agents. A review of clinical trials of novel therapeutic agents and their molecular targets is provided. In addition, a review of the current literature on other potential molecular targets for endometrial cancer was performed. Several phase II trials of novel agents, both alone and in combination with traditional cytotoxic chemotherapy, have been completed or are nearing completion. It appears that the targeted agents may have the most efficacy in combination with cytotoxic chemotherapy or in a multi-targeted agent approach. Chemotherapy offers the opportunity for a meaningful response rate in women with endometrial cancer, but the responses are often short lived and cure is uncommon in the setting of recurrent disease. The recent increase in molecular targets has led to the availability of many novel therapies. Determining how these agents are to be used, alone or in combination with “standard” therapies, needs to be defined and translational studies are needed to develop rational combinations of these novel agents before we can move into clinical trials.
登录
查看更多内容
DOI：
10.1016/j.jsbmb.2007.09.020
发表时间：
2008-02-01
影响因子：
4.1
作者：
Doll, A.;Abal, M.;Reventos, J.
通讯作者：
Reventos, J.
影响因子：
45.3
作者：
Dizon, Don S.;Blessing, John A.;Alvarez, Ronald D.
通讯作者：
Alvarez, Ronald D.
影响因子：
6.4
作者：
Bilbao, Cristina;Rodriguez, German;Perucho, Manuel
通讯作者：
Perucho, Manuel
影响因子：
4.7
作者：
Fine, BA;Valente, PT;Dey, T
通讯作者：
Dey, T
影响因子：
6.2
作者：
Dunton, C J;Balsara, G;Hernandez, E
通讯作者：
Hernandez, E